J V Mahendra1, Satish D Kumar2, T S Anuradha3, Prashanth Talikoti4, R S Nagaraj5, V Vishali1. 1. Associate Professor, Department of Neurology, M.S Ramaiah Medical College , Bangalore, India . 2. Associate Professor, Deparment of Biochemistry, ESIC Medical College , Gulbarga, India . 3. Senior Resident, Deparment of Radio Diagnosis, Rajrajeshwari Medical College , Bangalore, India . 4. Assistant Professor, Deparment of Biochemistry, ESIC Medical College , Gulbarga, India . 5. Tutor, Deparment of Biochemistry, ESIC Medical College , Gulbarga, India .
Abstract
INTRODUCTION: Metabolic syndrome or Syndrome X is characterized by hyperlipidemia, increased blood pressure, abdominal obesity and hyperglycemia, which increases the risk of cardiovascular complications. In addition to these, it is also associated with nontraditional risk factor like C- reactive protein, Plasminogen activator and fibrinogen. Various studies have documented association of these nontraditional risk factor, in Type 2 diabetes mellitus. Thus patients with diabetes mellitus are higher risk of developing micro and macro vascular complications like ischemic heart disease (IHD) and diabetic retinopathy. Diabetic retinopathy is the leading cause of decreased visual acuity, which is associated with maculopathy and profierative complications of it. Chronic hyperglycemia and its associated nonenzymatic glycation play an important role in the development of microangiopathy. AIMS AND OBJECTIVES: To study the prevalence of the metabolic syndrome in type 2 diabetes mellitus. To study the plasma fibrinogen and its relationship with IHD and retinopathy in type 2 Diabetes mellitus patients with metabolic syndrome. MATERIALS AND METHODS: Patients of type 2 diabetes Mellitus were recruited based on the inclusion and exclusion criteria. History of IHD and ECG evidence of ischemia was obtained. Retinopathy was diagnosed by direct opthalmoscopy. Fasting glucose, lipid profile and plasma fibrinogen were analyzed. Stastical analysis was carried by Chi square test and student't' test. RESULTS: The prevalence of metabolic syndrome in study population of 100 type 2 diabetic patients is 58% and is significantly associated with duration of the disease (p<0.001). Fifty eight patients have hyperfibrinogenemia and mean fibrinogen level is significantly high in diabetic patients with metabolic syndrome when compared to diabetic patients without metabolic syndrome (p<0.001). Diabetic patient with metabolic syndrome and hyperfibrinogenemia have higher prevalence of IHD and retinopathy in comparison with diabetic patients without metabolic syndrome (p<0.05). CONCLUSION: The prevalence of metabolic syndrome is higher in type 2 Diabetes mellitus patients. The combination of metabolic syndrome and hyperfibrinogenemia increases the risk of developing micro and macro vascular complications.
INTRODUCTION:Metabolic syndrome or Syndrome X is characterized by hyperlipidemia, increased blood pressure, abdominal obesity and hyperglycemia, which increases the risk of cardiovascular complications. In addition to these, it is also associated with nontraditional risk factor like C- reactive protein, Plasminogen activator and fibrinogen. Various studies have documented association of these nontraditional risk factor, in Type 2 diabetes mellitus. Thus patients with diabetes mellitus are higher risk of developing micro and macro vascular complications like ischemic heart disease (IHD) and diabetic retinopathy. Diabetic retinopathy is the leading cause of decreased visual acuity, which is associated with maculopathy and profierative complications of it. Chronic hyperglycemia and its associated nonenzymatic glycation play an important role in the development of microangiopathy. AIMS AND OBJECTIVES: To study the prevalence of the metabolic syndrome in type 2 diabetes mellitus. To study the plasma fibrinogen and its relationship with IHD and retinopathy in type 2 Diabetes mellituspatients with metabolic syndrome. MATERIALS AND METHODS:Patients of type 2 diabetes Mellitus were recruited based on the inclusion and exclusion criteria. History of IHD and ECG evidence of ischemia was obtained. Retinopathy was diagnosed by direct opthalmoscopy. Fasting glucose, lipid profile and plasma fibrinogen were analyzed. Stastical analysis was carried by Chi square test and student't' test. RESULTS: The prevalence of metabolic syndrome in study population of 100 type 2 diabeticpatients is 58% and is significantly associated with duration of the disease (p<0.001). Fifty eight patients have hyperfibrinogenemia and mean fibrinogen level is significantly high in diabeticpatients with metabolic syndrome when compared to diabeticpatients without metabolic syndrome (p<0.001). Diabeticpatient with metabolic syndrome and hyperfibrinogenemia have higher prevalence of IHD and retinopathy in comparison with diabeticpatients without metabolic syndrome (p<0.05). CONCLUSION: The prevalence of metabolic syndrome is higher in type 2 Diabetes mellituspatients. The combination of metabolic syndrome and hyperfibrinogenemia increases the risk of developing micro and macro vascular complications.
Authors: David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw Journal: Diabetes Care Date: 2002-05 Impact factor: 19.112
Authors: Pedro Marques-Vidal; Elizabeth Mazoyer; Vanina Bongard; Pierre Gourdy; Jean-Bernard Ruidavets; Ludovic Drouet; Jean Ferrières Journal: Diabetes Care Date: 2002-08 Impact factor: 19.112
Authors: Eduardo Menti; Denise Zaffari; Thais Galarraga; João Regis da Conceição E Lessa; Bruna Pontin; Lucia Campos Pellanda; Vera Lúcia Portal Journal: Arq Bras Cardiol Date: 2016-05-03 Impact factor: 2.000